MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)

MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)

Show other versions (1)

The aim of oral tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) is to get ideal hematological, cytogenetic, molecular responses at the critical time-points. The depth of the response obtained with TKI and time to achieve this response are important for the prediction of p...

Full description

Saved in:

Bibliographic Details
Main Author:	Ibrahim C. Haznedaroglu
Format:	Article
Language:	English
Published:	PAGEPress Publications 2013-12-01
Series:	Mediterranean Journal of Hematology and Infectious Diseases
Subjects:	Leukemia
Online Access:	http://www.mjhid.org/index.php/mjhid/article/view/1358
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Monitoring the response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML)
by: Ibrahim C. Haznedaroglu
Published: (2014-08-01)

Role of MicroRNAs in Chronic Myeloid Leukemia (CML) Treatment, Biomarkers, and Resistance to Tyrosine Kinase Inhibitor: A Bioinformatics-Based Analysis
by: Syarifah Faezah binti Syed Mohamad, et al.
Published: (2024-11-01)

Mild clinical course of COVID-19 infection in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKIs) without interruption
by: Judit Demeter, et al.
Published: (2021-02-01)

DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE
by: Ibrahim C. Haznedaroglu
Published: (2015-02-01)

Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in South Africa
by: Rochelle Woudberg, et al.
Published: (2025-01-01)

Cerebrovascular stenosis related to tyrosine kinase inhibitor for chronic myeloid leukemia: two illustrative cases
by: Nozomi Sasaki, et al.
Published: (2025-01-01)

Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
by: Kotlyarchuk K., et al.
Published: (2015-09-01)

Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
by: K. Kotlyarchuk, et al.
Published: (2015-09-01)

IS ALLOGENEIC TRANPLANTATION AN OPTION IN PATIENTS AFFECTED BY CONCURRENT MYELOFIBROSIS AND CHRONIC MYELOID LEUKEMIA (CML)?
by: Federica Sorà, et al.
Published: (2021-10-01)

Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study
by: Junichiro Yuda, et al.
Published: (2023-02-01)

SOCIAL AND FINANCIAL BARRIERS TO OPTIMUM TKI TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA- A KNOWLEDGE-ATTITUDES-PRACTICES STUDY FROM INDIA
by: Naveen Gupta, et al.
Published: (2021-01-01)

Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison
by: Valentin Garcia-Gutierrez, et al.
Published: (2024-11-01)

TYROSINE KINASE INHIBITORS AND INTERFERON
by: Maria Dimou, et al.
Published: (2014-01-01)

Discovery of natural compounds as novel FMS-like tyrosine kinase-3 (FLT3) therapeutic inhibitors for the treatment of acute myeloid leukemia: An in-silico approach
by: Uddalak Das, et al.
Published: (2025-06-01)

Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on Behalf of the Polish Adult Leukemia Group
by: Ugo Giordano, et al.
Published: (2025-01-01)

The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemia
by: Xiaoxia Wu, et al.
Published: (2024-09-01)

Chronic myeloid leukemia following nasopharyngeal carcinoma
by: olfa kassar
Published: (2014-08-01)

Molecular, Cytogenetic, and Hematological Monitoring and Response to Treatment for Chronic Myeloid Leukemia Patients
by: Noor Al-Huda Bahar, et al.
Published: (2024-12-01)

IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
by: Tomasz Sacha
Published: (2013-12-01)

FREQUENCY OF FMS-LIKE TYROSINE KINASE 3 KINASE DOMAIN POINT MUTATION (FLT3/TKD MUTATION) IN DIFFERENT AGE GROUPS OF ACUTE MYELOID LEUKEMIA PATIENTS.
by: Khaleeq unnisa, et al.
Published: (2014-08-01)

Low Renalase Levels in Newly Diagnosed CML: Dysregulation Sensitive to Modulation by Tyrosine Kinase Inhibitors
by: Jelena Milenkovic, et al.
Published: (2024-12-01)

TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
by: Michele Baccarani, et al.
Published: (2014-01-01)

REPEATED THERAPEUTIC LEUKAPHERESIS - A SOLE TREATMENT DURING PREGNANCY AS A BRIDGE BEFORE TYROSINE KINASE INHIBITORS FOR A PREGNANT WOMAN WITH CHRONIC MYELOGENOUS LEUKEMIA – A CASE REPORT AND DISCUSSION
by: Ivan Tonev, et al.
Published: (2025-01-01)

SECOND-GENERATION TYROSINE KINASE INHIBITORS (TKI) AS SALVAGE THERAPY FOR RESISTANT OR INTOLERANT PATIENTS TO PRIOR TKIs
by: Massimo Breccia, et al.
Published: (2014-01-01)

Aplasia in Chronic Phase CML Post-TKI Therapy: A Management Dilemma
by: Jeremy L. Ramdial, et al.
Published: (2019-01-01)

Correlation analysis of bone marrow microvessel density and miRNA expression on drug resistance in patients with chronic myelogenous leukemia after tyrosine kinase inhibitor treatment
by: Yi-gang Guo, et al.
Published: (2024-12-01)

Tyrosine Kinase Inhibitor-Induced Intracranial Artery Stenosis – A Rare Cause of TIA in a Patient of Chronic Myeloid Leukemia
by: Sumedh S Agrawal, et al.
Published: (2024-12-01)

Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead
by: Kalyan V. G. Nadiminti, et al.
Published: (2024-11-01)

Bruton’s tyrosine kinase inhibitor associated localized extremity edema and erythema
by: Shannon Meledathu, BS, et al.
Published: (2024-12-01)

Treatment Interruption and Regimen Change in Firstgeneration versus Second-generation Tyrosine Kinase Inhibitors used as First-line Therapy for Chronic Myeloid Leukemia
by: Melea A. Ward, et al.
Published: (2015-04-01)

Rechallenge therapy versus tyrosine kinase inhibitor (TKI) for advanced metastatic colorectal cancer: a retrospective study
by: Chenming Liu, et al.
Published: (2025-02-01)

Delayed manifestation of proliferative retinopathy associated with chronic myeloid leukemia
by: Alan Chew Bonilla, et al.
Published: (2024-12-01)

CHRONIC MYELOGENOUS LEUKEMIA (CML) IN THE ELDERLY
by: Lodovico Balducci
Published: (2014-05-01)

Acute Panmyelosis with Myelofibrosis - A Rare Subtype of Acute Myeloid Leukemia
by: Tathagata Chatterjee, et al.
Published: (2013-06-01)

OUTCOME OF FRONTLINE TREATMENT WITH “GENERIC” IMATINIB IN ADULT PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN ALGERIAN POPULATION: A MULTICENTER STUDY
by: Mohamed Amine BEKADJA
Published: (2017-10-01)

Treatment with low-dose tyrosine kinase inhibitors due to significant haematologic toxicity in patients with CML with prolonged treatment failure prevents haematologic progression
by: Lucia Vráblová, et al.
Published: (2024-12-01)

INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER
by: Caterina Giovanna Valentini, et al.
Published: (2011-12-01)

INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER
by: Morena Caira, et al.
Published: (2011-01-01)

OPTIMIZATION OF TKI SELECTION IN CML: BALANCING EFFICACY, SAFETY, AND PATIENT PREFERENCES
by: Emel İşleyen Kaya
Published: (2024-12-01)

Health-Related Quality of Life and Financial Burden in Ethiopian Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Study
by: Fisihatsion Tadesse, et al.
Published: (2024-11-01)